{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:48:32Z","timestamp":1791478112448,"version":"4.3.4"},"reference-count":73,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T00:00:00Z","timestamp":1642636800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s13311-021-01178-4","type":"journal-article","created":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T16:11:05Z","timestamp":1642695065000},"page":"823-831","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"title":["Antibody Therapies in Autoimmune Encephalitis"],"prefix":"10.1016","volume":"19","author":[{"given":"I.","family":"Smets","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1033-3840","authenticated-orcid":false,"given":"M.J.","family":"Titulaer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-021-01178-4_bib1","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/ana.21050","article-title":"Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma","volume":"61","author":"Dalmau","year":"2007","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-021-01178-4_bib2","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1474-4422(15)00401-9","article-title":"A clinical approach to diagnosis of autoimmune encephalitis","volume":"15","author":"Graus","year":"2016","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-021-01178-4_bib3","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S1474-4422(10)70137-X","article-title":"Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series","volume":"9","author":"Lai","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-021-01178-4_bib4","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1093\/brain\/awt212","article-title":"Faciobrachial dystonic seizures: the influence of immunotherapy on seizure control and prevention of cognitive impairment in a broadening phenotype","volume":"136","author":"Irani","year":"2013","journal-title":"Brain"},{"key":"10.1007\/s13311-021-01178-4_bib5","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1212\/WNL.0000000000003173","article-title":"Anti-LGI1 encephalitis: clinical syndrome and long-term follow-up","volume":"87","author":"van Sonderen","year":"2016","journal-title":"Neurology"},{"key":"10.1007\/s13311-021-01178-4_bib6","first-page":"2734","article-title":"Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis","volume":"133","author":"Irani","year":"2010","journal-title":"Morvan's syndrome and acquired neuromyotonia Brain"},{"key":"10.1007\/s13311-021-01178-4_bib7","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/ana.21589","article-title":"AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location","volume":"65","author":"Lai","year":"2009","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-021-01178-4_bib8","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1212\/WNL.0000000000002917","article-title":"The clinical spectrum of Caspr2 antibody-associated disease","volume":"87","author":"van Sonderen","year":"2016","journal-title":"Neurology"},{"key":"10.1007\/s13311-021-01178-4_bib9","doi-asserted-by":"crossref","unstructured":"Graus F, Vogrig A, Mu\u00f1iz-Castrillo S, Antoine JCG, Desestret V, Dubey D, Giometto B, Irani SR, Joubert B, Leypoldt F, et al. Updated diagnostic criteria for paraneoplastic neurologic syndromes. Neurol Neuroimmunol. 2021;8. https:\/\/doi.org\/10.1212\/NXI.0000000000001014.","DOI":"10.1212\/NXI.0000000000001014"},{"key":"10.1007\/s13311-021-01178-4_bib10","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/nrneurol.2012.99","article-title":"Neuronal autoantigens-pathogenesis, associated disorders and antibody testing","volume":"8","author":"Lancaster","year":"2012","journal-title":"Nat Rev Neurol"},{"key":"10.1007\/s13311-021-01178-4_bib11","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.autrev.2013.10.016","article-title":"Molecular and cellular mechanisms underlying anti-neuronal antibody mediated disorders of the central nervous system","volume":"13","author":"Van Coevorden-Hameete","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1007\/s13311-021-01178-4_bib12","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S1474-4422(11)70096-5","article-title":"Autoantibodies associated with diseases of the CNS: New developments and future challenges","volume":"10","author":"Vincent","year":"2011","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-021-01178-4_bib13","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1152\/physrev.00010.2016","article-title":"Autoantibodies to synaptic receptors and neuronal cell surface proteins in autoimmune diseases of the central nervous system","volume":"97","author":"Dalmau","year":"2017","journal-title":"Physiol Rev"},{"key":"10.1007\/s13311-021-01178-4_bib14","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1093\/brain\/awq113","article-title":"N-methyl-d-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes","volume":"133","author":"Irani","year":"2010","journal-title":"Brain"},{"key":"10.1007\/s13311-021-01178-4_bib15","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1474-4422(12)70310-1","article-title":"Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study","volume":"12","author":"Titulaer","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-021-01178-4_bib16","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1136\/jnnp-2020-325300","article-title":"Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management","volume":"92","author":"Abboud","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-021-01178-4_bib17","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1136\/jnnp-2020-325302","article-title":"Autoimmune encephalitis: proposed recommendations for symptomatic and long-term management","volume":"92","author":"Abboud","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-021-01178-4_bib18","doi-asserted-by":"crossref","unstructured":"de Vries JM, Titulaer MJ. Treatment approaches in autoimmune neurology: focus on autoimmune encephalitis with neuronal cell surface antibodies, in Neuroimmunology: Multiple Sclerosis, Autoimmune Neurology and Related Diseases, eds. A. L. Piquet, E. Alvarez (Cham: Springer International Publishing), 261\u2013278. https:\/\/doi.org\/10.1007\/978-3-030-61883-4_17.","DOI":"10.1007\/978-3-030-61883-4_17"},{"key":"10.1007\/s13311-021-01178-4_bib19","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1212\/WNL.0000000000003009","article-title":"Anti-LGI1\u2013associated cognitive impairment","volume":"87","author":"Ari\u00f1o","year":"2016","journal-title":"Neurology"},{"key":"10.1007\/s13311-021-01178-4_bib20","doi-asserted-by":"crossref","unstructured":"Shin YW, Lee ST, Shin JW, Moon J, Lim JA, Byun JI, Kim TJ, Lee KJ, Kim YS, Park K Il, et al. VGKC-complex\/LGI1-antibody encephalitis: clinical manifestations and response to immunotherapy. J Neuroimmunol. 2013;265:75\u201381. https:\/\/doi.org\/10.1016\/j.jneuroim.2013.10.005.","DOI":"10.1016\/j.jneuroim.2013.10.005"},{"key":"10.1007\/s13311-021-01178-4_bib21","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1586\/14737175.2015.1115720","article-title":"Immune therapy in autoimmune encephalitis: a systematic review","volume":"15","author":"Nosadini","year":"2015","journal-title":"Expert Rev Neurother"},{"key":"10.1007\/s13311-021-01178-4_bib22","doi-asserted-by":"crossref","unstructured":"Thaler FS, Zimmermann L, Kammermeier S, Strippel C, Ringelstein M, Kraft A, S\u00fchs KW, Wickel J, Geis C, Markewitz R, et al. Rituximab treatment and long-term outcome of patients with autoimmune encephalitis: real-world evidence from the GENERATE Registry. Neurol Neuroimmunol. 2021;8. https:\/\/doi.org\/10.1212\/NXI.0000000000001088.","DOI":"10.1212\/NXI.0000000000001088"},{"key":"10.1007\/s13311-021-01178-4_bib23","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/ane.13291","article-title":"Efficacy and safety of rituximab in autoimmune encephalitis: a meta-analysis","volume":"142","author":"Nepal","year":"2020","journal-title":"Acta Neurol Scand"},{"key":"10.1007\/s13311-021-01178-4_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/NXI.0000000000000696","article-title":"Neurologic syndromes related to anti-GAD65: clinical and serologic response to treatment","volume":"7","author":"Mu\u00f1oz-Lopetegi","year":"2020","journal-title":"Neurol Neuroimmunol neuroinflammation"},{"key":"10.1007\/s13311-021-01178-4_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fneur.2020.602102","article-title":"Case report: daratumumab in a patient with severe refractory anti-NMDA receptor encephalitis","volume":"11","author":"Ratuszny","year":"2020","journal-title":"Front Neurol"},{"key":"10.1007\/s13311-021-01178-4_bib26","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00415-019-09585-6","article-title":"Daratumumab treatment for therapy-refractory anti-CASPR2 encephalitis","volume":"267","author":"Scheibe","year":"2020","journal-title":"J Neurol"},{"key":"10.1007\/s13311-021-01178-4_bib27","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1001\/jamaneurol.2013.143","article-title":"Successful treatment of anti-caspr2 syndrome by interleukin 6 receptor blockade through tocilizumab","volume":"70","author":"Krogias","year":"2013","journal-title":"JAMA Neurol"},{"key":"10.1007\/s13311-021-01178-4_bib28","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1007\/s13311-016-0442-6","article-title":"Tocilizumab in autoimmune encephalitis refractory to rituximab: an institutional cohort study","volume":"13","author":"Lee","year":"2016","journal-title":"Neurotherapeutics"},{"key":"10.1007\/s13311-021-01178-4_bib29","doi-asserted-by":"crossref","unstructured":"Lee WJ, Lee ST, Shin YW, Lee HS, Shin HR, Kim DY, Kim S, Lim JA, Moon J, Park K Il, et al. Teratoma removal, steroid, IVIG, rituximab and tocilizumab (T-SIRT) in anti-NMDAR encephalitis. Neurotherapeutics. 2021;18:474\u2013487. https:\/\/doi.org\/10.1007\/s13311-020-00921-7.","DOI":"10.1007\/s13311-020-00921-7"},{"key":"10.1007\/s13311-021-01178-4_bib30","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.2217\/fon.14.146","article-title":"Rituximab: modes of action, remaining dispute and future perspective","volume":"10","author":"Abulayha","year":"2014","journal-title":"Futur Oncol"},{"key":"10.1007\/s13311-021-01178-4_bib31","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S1474-4422(13)70282-5","article-title":"Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study","volume":"13","author":"Gresa-Arribas","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-021-01178-4_bib32","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1212\/WNL.0b013e318228c136","article-title":"Analysis of complement and plasma cells in the brain of patients with anti-NMDAR encephalitis","volume":"77","author":"Martinez-Hernandez","year":"2011","journal-title":"Neurology"},{"key":"10.1007\/s13311-021-01178-4_bib33","unstructured":"EMA. Summary of product characteristics rituximab. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/mabthera-epar-product-information_en.pdf [Accessed 7 July 2021]."},{"key":"10.1007\/s13311-021-01178-4_bib34","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000463","article-title":"Monitoring B-cell repopulation after depletion therapy in neurologic patients","volume":"5","author":"Ellwardt","year":"2018","journal-title":"Neurol - Neuroimmunol Neuroinflammation"},{"key":"10.1007\/s13311-021-01178-4_bib35","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000130","article-title":"Earlier treatment of NMDAR antibody encephalitis in children results in a better outcome: Table 1","volume":"2","author":"Byrne","year":"2015","journal-title":"Neurol - Neuroimmunol Neuroinflammation"},{"key":"10.1007\/s13311-021-01178-4_bib36","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S1474-4422(19)30244-3","article-title":"An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models","volume":"18","author":"Dalmau","year":"2019","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-021-01178-4_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/NXI.0000000000001039","article-title":"Autoimmune encephalitis resembling dementia syndromes","volume":"8","author":"Bastiaansen","year":"2021","journal-title":"Neurol Neuroimmunol neuroinflammation"},{"key":"10.1007\/s13311-021-01178-4_bib38","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/jamaneurol.2013.3071","article-title":"A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder","volume":"70","author":"Kim","year":"2013","journal-title":"JAMA Neurol"},{"key":"10.1007\/s13311-021-01178-4_bib39","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1212\/WNL.0000000000002635","article-title":"Rituximab treatment for autoimmune limbic encephalitis in an institutional cohort","volume":"86","author":"Lee","year":"2016","journal-title":"Neurology"},{"key":"10.1007\/s13311-021-01178-4_bib40","doi-asserted-by":"crossref","unstructured":"Mrak D, Tobudic S, Koblischke M, Graninger M, Radner H, Sieghart D, Hofer P, Perkmann T, Haslacher H, Thalhammer R, et al. SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity. Ann Rheum Dis. 2021;1\u20136. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220781.","DOI":"10.1136\/annrheumdis-2021-220781"},{"key":"10.1007\/s13311-021-01178-4_bib41","article-title":"Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies","volume":"14","author":"Achiron","year":"2021","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1007\/s13311-021-01178-4_bib42","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/WCO.0000000000000443","article-title":"Autoimmune encephalitis in children: clinical phenomenology, therapeutics, and emerging challenges","volume":"30","author":"Dale","year":"2017","journal-title":"Curr Opin Neurol"},{"key":"10.1007\/s13311-021-01178-4_bib43","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1007\/s00415-016-8282-1","article-title":"Clinical characteristics and outcomes between children and adults with anti-N-methyl-d-aspartate receptor encephalitis","volume":"263","author":"Huang","year":"2016","journal-title":"J Neurol"},{"key":"10.1007\/s13311-021-01178-4_bib44","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1212\/WNL.0000000000000570","article-title":"Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease","volume":"83","author":"Dale","year":"2014","journal-title":"Neurology"},{"key":"10.1007\/s13311-021-01178-4_bib45","doi-asserted-by":"crossref","unstructured":"Nosadini M, Alper G, Riney CJ, Benson LA, Mohammad SS, Ramanathan S, Nolan M, Appleton R, Leventer RJ, Deiva K, et al. Rituximab monitoring and redosing in pediatric neuromyelitis optica spectrum disorder. Neurol Neuroimmunol NeuroInflammation. 2016;3. https:\/\/doi.org\/10.1212\/NXI.0000000000000188.","DOI":"10.1212\/NXI.0000000000000188"},{"key":"10.1007\/s13311-021-01178-4_bib46","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/14728222.2021.1856370","article-title":"Autoimmune encephalitis: novel therapeutic targets at the preclinical level","volume":"25","author":"Sell","year":"2021","journal-title":"Expert Opin Ther Targets"},{"key":"10.1007\/s13311-021-01178-4_bib47","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.msard.2016.01.001","article-title":"The effects of intrathecal rituximab on biomarkers in multiple sclerosis","volume":"6","author":"Topping","year":"2016","journal-title":"Mult Scler Relat Disord"},{"key":"10.1007\/s13311-021-01178-4_bib48","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000079","article-title":"Rapid depletion of B lymphocytes by ultra-low-dose rituximab delivered intrathecally","volume":"2","author":"Svenningsson","year":"2015","journal-title":"Neurol Neuroimmunol NeuroInflammation"},{"key":"10.1007\/s13311-021-01178-4_bib49","doi-asserted-by":"crossref","first-page":"E1893","DOI":"10.1212\/WNL.0000000000006500","article-title":"Intrathecal treatment trial of rituximab in progressive ms an open-label phase 1b study","volume":"91","author":"Bergman","year":"2018","journal-title":"Neurology"},{"key":"10.1007\/s13311-021-01178-4_bib50","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.msard.2019.02.013","article-title":"Trial of intrathecal rituximab in progressive multiple sclerosis patients with evidence of leptomeningeal contrast enhancement","volume":"30","author":"Bhargava","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"10.1007\/s13311-021-01178-4_bib51","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s40263-020-00704-w","article-title":"Anti-CD20 monoclonal antibodies for relapsing and progressive multiple sclerosis","volume":"34","author":"Sellebjerg","year":"2020","journal-title":"CNS Drugs"},{"key":"10.1007\/s13311-021-01178-4_bib52","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1097\/JNN.0000000000000450","article-title":"Successful intrathecal rituximab administration in refractory nonteratoma anti- N -methyl-D-aspartate receptor encephalitis: a case report","volume":"51","author":"Casares","year":"2019","journal-title":"J Neurosci Nurs"},{"key":"10.1007\/s13311-021-01178-4_bib53","doi-asserted-by":"crossref","first-page":"E2185","DOI":"10.1212\/WNL.0000000000007475","article-title":"Evaluation of seizure treatment in anti-LGI1, anti-NMDAR, and anti-GABABR encephalitis","volume":"92","author":"De Bruijn","year":"2019","journal-title":"Neurology"},{"key":"10.1007\/s13311-021-01178-4_bib54","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4161\/mabs.22771","article-title":"Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties","volume":"5","author":"Klein","year":"2013","journal-title":"MAbs"},{"key":"10.1007\/s13311-021-01178-4_bib55","unstructured":"EMA. Summary of product characteristics ocrelizumab. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ocrevus-epar-product-information_en.pdf [Accessed 7 July 2021]."},{"key":"10.1007\/s13311-021-01178-4_bib56","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S1474-4422(20)30392-6","article-title":"New therapies for neuromyelitis optica spectrum disorder","volume":"20","author":"Levy","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-021-01178-4_bib57","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet"},{"key":"10.1007\/s13311-021-01178-4_bib58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s42466-019-0037-x","article-title":"General principles and escalation options of immunotherapy in autoantibody-associated disorders of the CNS","volume":"1","author":"Ayzenberg","year":"2019","journal-title":"Neurol Res Pract"},{"key":"10.1007\/s13311-021-01178-4_bib59","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/intimm\/dxu081","article-title":"Therapeutic uses of anti-interleukin-6 receptor antibody","volume":"27","author":"Kang","year":"2015","journal-title":"Int Immunol"},{"key":"10.1007\/s13311-021-01178-4_bib60","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1474-4422(20)30070-3","article-title":"Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial","volume":"19","author":"Zhang","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-021-01178-4_bib61","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1001\/jamaneurol.2015.0533","article-title":"Long-term therapy with interleukin 6 receptor blockade in highly active neuromyelitis optica spectrum disorder","volume":"72","author":"Ringelstein","year":"2015","journal-title":"JAMA Neurol"},{"key":"10.1007\/s13311-021-01178-4_bib62","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1158\/1078-0432.CCR-14-2291","article-title":"Interleukin-6 as a therapeutic target","volume":"21","author":"Rossi","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1007\/s13311-021-01178-4_bib63","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of satralizumab in neuromyelitis optica spectrum disorder","volume":"381","author":"Yamamura","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-021-01178-4_bib64","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","article-title":"Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial","volume":"19","author":"Traboulsee","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-021-01178-4_bib65","doi-asserted-by":"crossref","unstructured":"Howard JF, Bril V, Burns TM, Mantegazza R, Bilinska M, Szczudlik A, Beydoun S, Garrido FJRDR, Piehl F, Rottoli M, et al. Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. Neurology 2019;92:e2661\u2013e2673. https:\/\/doi.org\/10.1212\/WNL.0000000000007600.","DOI":"10.1212\/WNL.0000000000007600"},{"key":"10.1007\/s13311-021-01178-4_bib66","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-021-01178-4_bib67","first-page":"1111","article-title":"Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration","volume":"10","author":"Smith","year":"2018","journal-title":"MAbs"},{"key":"10.1007\/s13311-021-01178-4_bib68","doi-asserted-by":"crossref","first-page":"e853","DOI":"10.1212\/WNL.0000000000011108","article-title":"Efficacy and safety of rozanolixizumab in moderate to severe generalized myasthenia gravis: a phase 2 randomized control trial","volume":"96","author":"Bril","year":"2021","journal-title":"Neurology"},{"key":"10.1007\/s13311-021-01178-4_bib69","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-021-01178-4_bib70","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/mus.26447","article-title":"Long-term safety and efficacy of eculizumab in generalized myasthenia gravis","volume":"60","author":"Muppidi","year":"2019","journal-title":"Muscle Nerve"},{"key":"10.1007\/s13311-021-01178-4_bib71","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4\u2013positive neuromyelitis optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-021-01178-4_bib72","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1093\/brain\/aws082","article-title":"Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis","volume":"135","author":"Bien","year":"2012","journal-title":"Brain"},{"key":"10.1007\/s13311-021-01178-4_bib73","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1002\/ana.26223","article-title":"Neuropathological variability within a spectrum of NMDAR-encephalitis","volume":"90","author":"Zrzavy","year":"2021","journal-title":"Ann Neurol"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-021-01178-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13311-021-01178-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923011054?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923011054?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-021-01178-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:56:08Z","timestamp":1761807368000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923011054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":73,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S1878747923011054"],"URL":"https:\/\/doi.org\/10.1007\/s13311-021-01178-4","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibody Therapies in Autoimmune Encephalitis","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-021-01178-4","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 The authors. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}